← Back to Analyst Consensus 
KLRS Buy
Kalaris Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 18, 2026 (22 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jun 15, 2026 | TD Cowen | initiate | — → Buy | — | 54% |
| May 14, 2026 | Wedbush | initiate | — → Outperform | — | 58% |
| May 13, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Apr 16, 2026 | Morgan Stanley | initiate | — → Overweight | — | 54% |
| Dec 23, 2025 | Chardan Capital | initiate | — → Buy | $19 | 47% |
| Nov 3, 2025 | Citizens | initiate | — → Market Outperform | $20 | 47% |
| Sep 3, 2025 | Raymond James | initiate | — → Strong Buy | $23 | 54% |
| Apr 8, 2025 | William Blair | initiate | — → Outperform | $0 | 48% |
Price Target Trend
Apr 3, 2026 Oct 27, 2026
EPS Estimates
+1q —
+1y —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days